A detailed history of Advisor Group Holdings, Inc. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 1,129 shares of RNA stock, worth $35,202. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,129
Previous 601 87.85%
Holding current value
$35,202
Previous $24,000 112.5%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$37.21 - $48.14 $19,646 - $25,417
528 Added 87.85%
1,129 $51,000
Q2 2024

Aug 13, 2024

BUY
$22.73 - $40.85 $10,592 - $19,036
466 Added 345.19%
601 $24,000
Q1 2024

May 10, 2024

SELL
$9.16 - $25.52 $3,664 - $10,208
-400 Reduced 74.77%
135 $3,000
Q4 2023

Feb 12, 2024

SELL
$4.87 - $9.37 $974 - $1,873
-200 Reduced 27.21%
535 $4,000
Q3 2023

Nov 13, 2023

BUY
$6.3 - $11.35 $2,507 - $4,517
398 Added 118.1%
735 $4,000
Q2 2023

Aug 10, 2023

SELL
$10.62 - $17.34 $2,676 - $4,369
-252 Reduced 42.78%
337 $3,000
Q1 2023

May 12, 2023

BUY
$15.35 - $25.65 $3,776 - $6,309
246 Added 71.72%
589 $9,000
Q4 2022

Feb 10, 2023

BUY
$10.06 - $22.66 $1,438 - $3,240
143 Added 71.5%
343 $7,000
Q1 2022

May 04, 2022

BUY
$14.2 - $23.78 $2,541 - $4,256
179 Added 852.38%
200 $3,000
Q3 2021

Nov 05, 2021

SELL
$18.16 - $25.21 $5,066 - $7,033
-279 Reduced 93.0%
21 $1,000
Q2 2021

Aug 02, 2021

SELL
$19.62 - $29.26 $4,905 - $7,315
-250 Reduced 45.45%
300 $7,000
Q1 2021

May 13, 2021

BUY
$20.28 - $28.15 $11,154 - $15,482
550 New
550 $12,000

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $1.63B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.